Cholangiocarcinoma Market Is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – Nucana, Agios Pharma, AstraZeneca, Merck, EMD Serono, QED Therapeutics, and Others

Delveinsight Business Research LLP
DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Cholangiocarcinoma Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Cholangiocarcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. 

Cholangiocarcinoma: An Overview

Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin in the biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumour may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect the gallbladder.

Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed with late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy.

Cholangiocarcinoma Market Key Facts

The total Cholangiocarcinoma diagnosed incident population in the 7MM was found to be 17,600+ in 2018. Among all the countries, the estimates show a higher incidence of Cholangiocarcinoma in the United States.

According to the Cholangiocarcinoma Foundation, about 8,000+ people in the US are diagnosed with cholangiocarcinoma each year. It can occur at younger ages but is most common in older people, and the average age of diagnosis is 70–75.

As per DelveInsight, the incidence rate varied based on type-specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extrahepatic CCA showed a decreasing trend or in some are stable cases.

In 2018, the Cholangiocarcinoma incident cases in Germany were found to be 2,600+.

Japan had 4,400+ Cholangiocarcinoma incident cases in 2018.

Cholangiocarcinoma Market

Cholangiocarcinoma Market size is anticipated to increase during the study period owing to the increasing Incident population of Cholangiocarcinoma (CCA) patients in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Cholangiocarcinoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Cholangiocarcinoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Cholangiocarcinoma Epidemiology

The epidemiology section covers insights into the historical and current Cholangiocarcinoma patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Cholangiocarcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholangiocarcinoma market or expected to get launched in the market during the study period. The analysis covers Cholangiocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Cholangiocarcinoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Cholangiocarcinoma Therapeutics Analysis

Some of the key companies in the Cholangiocarcinoma (CCA) Market include:

Agios Pharmaceuticals



EMD Serono

QED Therapeutics


Lexicon Pharmaceutical

And many others.

Cholangiocarcinoma (CCA) Therapies Covered in the Report Include:






Telotristat ethyl

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Cholangiocarcinoma Competitive Intelligence Analysis

4. Cholangiocarcinoma Market Overview at a Glance

5. Cholangiocarcinoma Disease Background and Overview

6. Cholangiocarcinoma Patient Journey

7. Cholangiocarcinoma Epidemiology and Patient Population

8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Cholangiocarcinoma Unmet Needs

10. Key Endpoints of Cholangiocarcinoma Treatment

11. Cholangiocarcinoma Marketed Products

12. Cholangiocarcinoma Emerging Therapies

13. Cholangiocarcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Cholangiocarcinoma Market Outlook (7 major markets)

16. Cholangiocarcinoma Access and Reimbursement Overview

17. KOL Views on the Cholangiocarcinoma Market.

18. Cholangiocarcinoma Market Drivers

19. Cholangiocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

Other Latest Reports By DelveInsight

Decompensated Cirrhosis Market

DelveInsight’s “Decompensated Cirrhosis Market” report delivers an in-depth understanding of the Decompensated Cirrhosis, historical and forecasted epidemiology as well as the Decompensated Cirrhosis market size, share, and trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States